Ellex Announces Six-Month Results on Retina Regenerati... (nd increased by more than 5 percent in o...)

Ellex Announces Six-Month Results on Retina Regeneration Therapy

Date:11/9/2008

nd increased by more than 5 percent in only 15 percent of

patients. In addition, the amount of hard exudates also decreased in more than half of the treated eyes. Visual acuity results: At six months, 43 percent of eyes had an improvement of two or more lines of LogMar visual acuity, while 28 percent showed an improvement of one to two lines of visual acuity.

The visual acuity remained stable in 15 percent of eyes and deteriorated in 14 percent of eyes.

"The six-month results presented at the AAO by Professor Marshall confirm our belief that there is a way to successfully treat diabetic macular edema safely and effectively without a significant visual trade-off," said Simon Luscombe, Ellex CEO. "Our next step is to expand clinical studies to investigate the therapeutic role of Ellex 2RT in other diseases that impact the retinal pigment epithelium, including early Age-Related Macular Degeneration (AMD), drusen and central serous retinopathy."

Ellex confirmed that it has commenced trials in Australia to further validate the effectiveness of Ellex 2RT. This includes double blind randomized control studies for treating Diabetic Macula Edema and Diabetic Retinopathy in conjunction with the South Australian Institute of Ophthalmology and the Royal Adelaide Hospital. An early AMD trial is also planned with the Royal Victorian Eye and Ear Hospital. Results from these trials are expected to be available in the second half of FY09. Further trials are also planned for London.

ABOUT ELLEX 2RT RESEARCH

Ellex 2RT research is funded in part by an A$1.9 million, two-year Commercial Ready Grant awarded to Ellex by the Australian Government to support the development of a new and innovative laser therapy for the treatment of Age-Related Macular Degeneration (AMD) and other retinal diseases. The grant was applied for in order to expand laboratory and clinical research in Australia based on proof- of-principle laboratory work conducted at St. T
'/>"/>

0

GOOD

Page: 1 2 3
Related medicine news :

1. Ellex Announces New Retina Regeneration Therapy to be Presented at the AAO
2. Ellex Commences Direct Sales in Germany
3. Ellex to Preview New Multi-Color Photocoagulation Laser at AAO
4. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
5. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. HEI, Inc. Announces Sale of RFID Division Assets
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
11. Brooke Franchise Corporation Announces Selected July Results

Post Your Comments:

Ellex Announces Six-Month Results on Retina Regenerati...(nd increased by more than 5 percent in o...),Health